Group One Trading’s Agile Therapeutics AGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-10
Closed -$20 8308
2023
Q4
$20 Hold
10
﹤0.01% 7248
2023
Q3
$24 Hold
10
﹤0.01% 7520
2023
Q2
$30 Sell
10
-2
-17% -$11 ﹤0.01% 7548
2023
Q1
$132 Hold
12
﹤0.01% 7021
2022
Q4
$134 Sell
12
-8
-40% -$93 ﹤0.01% 7060
2022
Q3
$0 Sell
20
-1
-5% -$25 ﹤0.01% 8533
2022
Q2
$1K Hold
21
﹤0.01% 7679
2022
Q1
$9K Buy
21
+5
+31% +$3.19K ﹤0.01% 7224
2021
Q4
$15K Sell
16
-7
-30% -$9.87K ﹤0.01% 7161
2021
Q3
$43K Buy
23
+5
+28% +$11.3K ﹤0.01% 6670
2021
Q2
$48K Buy
18
+11
+157% +$36.3K ﹤0.01% 6624
2021
Q1
$27K Sell
7
-36
-84% -$195K ﹤0.01% 6624
2020
Q4
$246K Hold
43
﹤0.01% 3908
2020
Q3
$260K Buy
43
+42
+4,200% +$241K ﹤0.01% 3440
2020
Q2
$7K Sell
1
-44
-98% -$229K ﹤0.01% 5285
2020
Q1
$169K Buy
45
+20
+80% +$115K ﹤0.01% 2891
2019
Q4
$124K Buy
25
+11
+79% +$38.4K ﹤0.01% 3502
2019
Q3
$33K Buy
14
+13
+1,300% +$32K ﹤0.01% 4175
2019
Q2
$2K Hold
1
﹤0.01% 4783
2019
Q1
$2K Hold
1
﹤0.01% 4618
2018
Q4
$1K Sell
1
-1
-50% -$1.53K ﹤0.01% 4764
2018
Q3
$1K Sell
2
-2
-50% -$1.46K ﹤0.01% 5096
2018
Q2
$4K Buy
4
+3
+300% +$10.5K ﹤0.01% 4866
2018
Q1
$5K Hold
1
﹤0.01% 4521
2017
Q4
$5K Buy
+1
New +$9.31K ﹤0.01% 4580

Other funds holding AGRX

Group One Trading's AGRX Position: Q1 2024 in Review

Group One Trading sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 10 shares — an estimated $20 sold.

Group One Trading first reported a position in AGRX in Q4 2017 and held it in 25 quarters. The position peaked at $260K in Q3 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.

  • Group One Trading reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Group One Trading sold 10 Agile Therapeutics shares in Q1 2024, an estimated $20.
  • Group One Trading first reported a position in Agile Therapeutics in Q4 2017 and held it in 25 quarters.
  • Group One Trading's Agile Therapeutics position peaked at $260K in Q3 2020.
  • 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.

Based on Group One Trading's 13F filing for Q1 2024, filed 10 May 2024.